House Subcommittee Includes 10% Increase For FDA
Top-Line:
House Subcommittee Includes 10% Increase For FDA
Alliance Supports House Subcommittee Mark
Next Hill Visits—June 22 and 23; Join us!
Alliance Unveils New Website: www.strengthenfda.org
Reported: Budget Negotiations Stall
FDA Space Requirements Re-Evaluated
This week’s Analysis and Commentary discusses the Alliance Senate meetings on June 22 and 23, encourages Alliance members and prospective members to join us, and explains the messages we will be delivering.
House Subcommittee Includes 10% Increase For FDA. The House Agriculture/FDA Appropriations Subcommittee marked up its FY23 funding bill. Under the bill, BA (budget authority) funding would reach $3.645 billion, an increase of $341 million (10%) and slightly more than the President’s Request.
According to the subcommittee summary: “Within this total, the Committee provides a targeted increase of $64 million for the opioid crisis, medical supply chain surveillance, drug safety surveillance and oversight, and increasing and strengthening in-person inspections of foreign drug manufacturers in India. It also includes a $77 million increase to better avoid or more quickly respond to food outbreaks, improve the animal food inspection system, and address heavy metals in baby food.”
The full committee mark-up the bill is scheduled for June 22. Floor consideration of appropriations bills is projected for July. Senate dates have not yet been announced and, if they follow prior years, those mark-ups will occur in late June and July. See the story below on the status of Senate negotiations on spending ceilings.
Alliance Supports House Subcommittee Mark. The Alliance released the following statement:
"The Alliance for a Stronger FDA is appreciative and fully supportive of the FY23 FDA funding proposed in the subcommittee bill. We applaud the leadership of Subcommittee Chair Sanford Bishop (D-MD) and Ranking Member Andy Harris (R-MD).
As reported in the subcommittee summary, FDA would receive a total of $3.645 billion in discretionary (budget authority) funding in the bill. This is an increase of $341 million (10%) above the FY 2022 enacted level.
The proposed increase is in line with the Alliance’s “ask” for FY 23 BA funding for FDA and is, reportedly, slightly larger than the President’s Budget Request.
As more detailed budget tables become available, we will provide policymakers, media, and FDA stakeholders with additional analysis."
Next Hill Visits -- June 22 and 23; Join us! The Alliance conducted more than 50 Hill visits during March and April. Our next round—concentrated on the Senate—will be on June 22 and 23. More details are in this week’s Analysis and Commentary (below). If you would like to participate, please contact Elisa Bayoumi.
Reported: Budget Negotiations Stall. Roll Call reports that Senate Appropriations Committee leaders disagree about how to proceed with spending bills. In broad terms, Democrats will favor an agreement that raises both defense and non-defense spending but would follow President Biden in providing a much larger percentage increase for non-defense programs.
Also, in broad terms, Republicans want far larger increases for defense spending and flat funding for non-defense programs. They have raised the possibility of funding the government on continuing resolutions until after the mid-term elections.
Alliance Unveils New Website: www.strengthenfda.org. The new site is content-rich and our goal, over time, is to make it even more useful. Please let us know if you have ideas about content related to FDA’s funding, mission, and responsibilities that you think would be valuable to Alliance members, policymakers, media, FDA stakeholders, and the public.
FDA Space Requirements Re-Evaluated. In the Alliance’s FY 23 budget priorities webinar series with FDA leadership (transcripts here), several Center directors mentioned more FDA employees working from home and improved ability to recruit product reviewers nationwide because they did not have to relocate to DC. Reportedly, because of those trends, a study is underway to see whether increases in remote office work might result in reduced demand for office space at White Oak.
